NCT06618079View on ClinicalTrials.gov

Drug-Drug Interaction Study Between HUC2-565-A and HUC2-565-B

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

April 20, 2024

Primary Completion Date

July 12, 2024

Study Completion Date

October 1, 2024

Conditions
Hypertension
Interventions
DRUG

HUC2-565-A, HUC2-565-A and HUC2-565-B

Cohort A received HUC2-565-A for 5 days, followed by HUC2-565-A and HUC2-565-B for 9 days.

DRUG

HUC2-565-B, HUC2-565-A and HUC2-565-B

Cohort B takes HUC2-565-B for 9 days, then HUC2-565-A and HUC2-565-B for 5 days.

Trial Locations (1)

28644

Chungbuk national university hospital, Jungbuk

All Listed Sponsors
lead

Huons Co., Ltd.

INDUSTRY

NCT06618079 - Drug-Drug Interaction Study Between HUC2-565-A and HUC2-565-B | Biotech Hunter | Biotech Hunter